Právní předpis byl sestaven k datu 13.01.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva zahraničních xxxx,
xxxxxx xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. října 2023 bylo xxxxxxxxx xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx rok 2024 - Xxxxxxxxxxx standard Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.
X xxxxx zněním Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx České xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx xxxxxxxxx x platnost xxx 18. června 2024 x nahradilo Xxxxxxx X pro rok 2023, platnou od 1. ledna 2023, xxxxx vstoupila v xxxxxxxx pro Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X pro xxx 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. JUDr. Xxxxxx, Ph.D., LL.M., x. x.
xxxxxx xxxxxxx xxxxx právní x xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Překlad xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx
Xxxx
Xxxxxx zakázaných xxxxx a xxxxx xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx antidopingového xxxxxxxx.
Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.
Oficiální xxxx Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx v xxxxxxxxxx x xxxxxxxxxxxxx. X případě jakýchkoliv xxxxxxxxxxxxx xxxx xxxxxxxxx x francouzským textem xxxxxxxxx xxxxx v xxxxxxxxxx.
Xxxx jsou uvedeny xxxxxxx pojmy xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx látek a xxxxx.
Xxxxxxxx Xxx soutěži
Pokud XXXX pro xxxx xxxxx neschválila xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx obdobím xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 xxxxx) x xxx předcházející Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x procesu xxxxxx Vzorku.
Zakázané xxxxx
Xx xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, xxx xx xxxxxxxxxx x Kodexu.
Specifické x Nespecifické
Podle článku 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „pro xxxxx xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Seznamu xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx metoda.“ Podle xxxxxxxxx k článku „Xxxxxxxxxx xxxxx a Xxxxxxxxxx xxxxxx xxxxxxx x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx nebezpečné xxx xxxx xxxxxxxxx xxxxx xxxx metody. Xxx xxxxx o xxxxx a xxxxxx, xxxxx Sportovec xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx výkonu.“
Návykové látky
Podle xxxxxx 4.2.3 Kodexu xxxx Návykové xxxxx xxxxxxxxxx jako xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxx xxxxxx častého xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Xxxxxxxx látky xxxx označovány xxxx xxxxx: xxxxxx, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 NESCHVÁLENÉ XXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Specifické látky.
Jakákoliv xxxxxxxxxxxxxx látka, na xxxxxx se nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není x xxxxxxxx xxxx schválena xxxxxx vládním xxxxxxxxxxxxx xxxxxxxxxx orgánem xxx xxxxxxx xxxxxxx x xxxx (xxxx. léčiva x předklinickém xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx veterinární xxxxxxx), xx xxxxxxxx xxxxx.
Xxxx xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (xxxx. Reldesemtiv x Tirasemtiv).
S1 XXXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.
Anabolické xxxxx xxxx xxxxxxxx.
X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)
Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion) |
• |
furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-hydroxy-5a-androst-1-en-17-on) |
• |
gestrinon |
|
|
• |
1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (androst-4-en-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on) |
|
|
• |
4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on) |
• |
metenolon |
|
|
• |
5-androstenedion (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (androst-4-en-3,17-dion) |
• |
norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
|
• |
calusteron |
• |
oxymesteron |
|
|
• |
klostebol |
• |
oxymetolon |
|
|
• |
danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on) |
|
|
• |
fluoxymesteron |
• |
trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT) |
a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými účinky.
S1.2. XXXXXXX ANABOLICKÉ LÁTKY
Mimo xxxx včetně:
Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů [SARM, xxxx. andarin, enobosarm (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, S-23 a XX-11], xxxxxxx x xxxxxxxxxx.
X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.
X2.1. ERYTROPOETINY (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx včetně:
S2.1.1 Xxxxxxxx erytropoetinových xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx na XXX, [xxxx. XXX-Xx, metoxypolyetylenglykol-epoetin xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, peginesatid.
S2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.
X2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.
X2.1.4 Inhibitory xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; sotatercept.
S2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ XXXXXXX
X2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x xxxx, xxxx xxxx včetně:
• xxxxxxxx xxxxxxxxxxxx (XX),
• xxxxxxxxxxxx xxxxxx (XX),
• xxxxxx xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) a xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x triptorelin),
• kisspeptin x xxxx xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx hormon (XX), xxxx analogy x xxxxxxxxx, mimo xxxx xxxxxx:
• xxxxxxx xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,
• fragmenty xxxxxxxxx xxxxxxx, např. XXX-9604 x xXX 176–191.
S2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. CJC-1293, CJC-1295, xxxxxxxxxx a xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx a tabimorelin],
• xxxxxxx uvolňující XX (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 x XXXX-6].
X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX
Xxxx xxxx včetně:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxxxxxxx růstový xxxxxx (XXX)
• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx růstové xxxxxxx (XXX)
• růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)
• xxxxxxxx-β4 x xxxx deriváty, xxxx. XX-500
• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)
x xxxxx růstové faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.
X3 BETA-2 AGONISTÉ
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxx látky.
Všichni selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx jsou xxxxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx dávce;
• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxx vyšším xxx 1000 ng/ml xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx považována xx Xxxxxxxxx xxxxxxxxxxx nález (XXX), pokud Xxxxxxxxx xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I MIMO XXXXXX)
Xxxxxxxx látky ve xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.
Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory xxxx xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx včetně:
|
• |
2-androstenol (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on) |
• |
androsta-3,5-dien-7,17-dion (arimistan) |
|
|
• |
3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on) |
• |
formestan |
|
|
• |
4-androsten-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. LÁTKY ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX AKTIVINU XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X |
• |
xxxxxxxxxx xxxxxxxxxx, xxxx.: |
|
|
• |
xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, např.: |
- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx myostatinu |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- proteiny xxxxxx myostatin (např. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx receptoru xxxxxxxx XXX (xxxx. bimagrumab) |
- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, stamulumab) |
S4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného receptoru xxxxx (XXXXδ), např. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , např. XX9009, XX9011
X4.4.2 xxxxxxxx x xxxxxxxx insulinů
S4.4.3 meldonium
S4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX X XXXXXXXXX LÁTKY
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx xxxxx jsou Specifické xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- a x-, xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Diuretika, xxxx xxxx.:
xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx etakrynová; furosemid; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; triamteren;
• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;
• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx intravenózně, např.:
albumin, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;
• Desmopresin;
• Xxxxxxxxxx;
x xxxxx látky x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• drospirenon; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamid, xxxxxxxxxxx);
• xxxxxxx podání xxxxxxxxxxx x xxxxx anestezii.
POZNÁMKA
Nález xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Soutěži xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (kromě lokálního xxxxxx podání inhibitoru xxxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) na xxxx xxxxx navíc x xx, xxxxx již xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx metody x xxxx třídě xxxx Xxxxxxxxxxxx x výjimkou xxxxx x X2.2, xxx jsou Specifické xxxxxx.
X1. MANIPULACE S XXXX X KREVNÍMI XXXXXXXXXXXX
Xxxxxxxx je následující:
M1.1. Xxxxxx xxxx opětovné xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, allogenní (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx z xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx x xxxxxxxx xxxxxxxx plazmy xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x registrovaném xxxxxxxxx xxxxxx.
X1.2. Umělé xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; efaproxiral (RSR13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx produkty, např. xxxxxx náhražky na xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx hemoglobinové produkty, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.
M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX MANIPULACE
Zakázané je xxxxxxxxxxx:
X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx účelem xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx odebraných při Xxxxxxxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx x/xxxx úprava Xxxxxx, xxxx. přidáním xxxxxxx xx Vzorku.
M2.2. Xxxxxxxxxx infuze a/nebo xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí legitimně xxxxxxxxx v průběhu xxxxxxxxxxxx ošetření, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. GENOVÝ X XXXXXXX DOPING
Z xxxxxx potencionálního xxxxxxx xxxxxxxxxxx výkonu je xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx a/nebo exprese xxxx xxxxxxxxxx mechanismem. Xx mimo jiné xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx.
X6 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky x xxxxxxxx látek xxxxxxxxx v S6.A, xxx xxxx Nespecifické xxxxx.
Xxxxxxxx látky x xxxx sekci: xxxxxx x metylendioxymetamfetamin (MDMA/„extáze“)
Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x l-, xxxx xxxxxxxx.
Xxxxxxxxxxx zahrnují:
S6.A: XXXXXXXXXXXX STIMULANCIA
|
• |
adrafinil |
• |
fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, který xxxx xxxxxxxx xxxxxx x xxxxx oddíle, xx Xxxxxxxxxxx xxxxxx.
X6.X: SPECIFICKÁ XXXXXXXXXXX
Xxxx xxxx včetně:
|
• |
2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxx (xxxxxxxxx) |
• |
xxxxxxxxxxx a xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (parahydroxyamfetamin) |
• |
fenmetrazin |
||
|
• |
benzfetamin |
• |
isomethepten |
• |
fenprometamin |
||
|
• |
katin1) |
• |
levmetamfetamin |
• |
propylhexedrin |
||
|
• |
katinon a xxxx xxxxxxx, např. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (dimetylamfetamin) |
• |
metylendioxymetamfetamin |
• |
selegilin |
||
|
• |
efedrin3) |
• |
metylefedrin3) |
• |
sibutramin |
||
|
• |
epinefrin (adrenalin)4) |
• |
metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx imidazolinu x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx použití (např. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 20245).
X7 XXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx látky.
Návykové xxxxx v xxxx xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx všech optických xxxxxxx, např. d- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x jeho xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (heroin) |
• |
metadon |
• |
oxykodon |
• |
tramadol |
|||
|
• |
oxymorfon |
S8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx zakázané, xxxx.
• x xxxxxx (hašiš, xxxxxxxxx) a konopných xxxxxxxxxx
• přírodní a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (THC)
• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• kanabidiol
S9 XXXXXXXXXXXXXXX
XXXXXXXX PŘI SOUTĚŽI
Všechny xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (např. bukální, xxxxxxxxxx, sublingvální)] xxxx xxxxxxxx xxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, intranazálního, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx zakázány, xxxxx se používají x rámci výrobcem xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X XXXXXXXX XXXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx x xxx xx to označeno xxxxxxxx (*) x Xxxx xxxxxx.
• xxxxxxxxxxx (XX)*
• lyžování/snowboarding (FIS) – xxxxx na xxxxxx, xxxxxxxxxxx skoky / X-xxxxx x xxxxxxxxx U-rampa / xxx xxx
• xxxxxxxxxxxx xxxxx (XXX)
• podvodní xxxxxx (CMAS)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx a xxxxxxx na xxxx
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• šipky (WDF)
• xxxx (IGF)
• xxxxxxxx (XXX)
• xxxxxxx (XXXX, XXX)*
* xxxxxxxx xxxx Xxxx xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;
1) xxxxx (x-xxxxxxxxxxxxxxxx) a jeho x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx vyšší xxx 150 xxxxxxxxxx x 1 xx.
3) xxxxxxx x metylefedrin: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 mikrogramů x 1 xx.
4) xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx anestetiky.
5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Zakázané xxxxx.
Informace
Právní xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx netýká derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu